The purpose of this study is to assess the efficacy of N-acetylcysteine (NAC) in preventing those with mild or moderate COVID-19 from progressing to severe disease
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Decrease in Respiratory Rate
Timeframe: First hour after first dose of NAC
Hospital length of stay (LOS)
Timeframe: Through study completion, average 9 months
Need for mechanical ventilation
Timeframe: Through study completion, average 9 months
Length of time intubated
Timeframe: Through study completion, average 9 months
Need for hospitalization
Timeframe: Through study completion, average 9 months
Recovery disposition
Timeframe: Through study completion, average 9 months